Google
NSRX 株価分析 — Nasus Pharma LTD. (Healthcare >> Drug Manufacturers - General)
NSRX に関するよくある質問
NSRXのROE（自己資本利益率）は？
Nasus Pharma LTD.のROEは-211.56%です。
NSRXの配当利回りは？
Nasus Pharma LTD.の配当利回りは0.00%です。
NSRXの品質スコア（Quality Score）は？
当社のAIはNSRXの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NSRXは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NSRXはどのセクターに属しますか？
Nasus Pharma LTD.はHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE MKT市場）
NSRX AI Analysis Summary
Our AI summary for NSRX: Nasus Pharma LTD. (NYSE MKT), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at ROE of -211.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.03
Price
-0.15
(-4.72%)
Day Change
|
|
|---|
NSRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
36% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.03 |
| PBV / Sector |
9.87 / 2.68
|
| Earning Per Share | -0.65 |
| PE / Sector |
N/A / 27.65
|
| PEG or PE/Growth / Sector |
N/A / 0.28
|
| Average 1M Daily Value |
0.04 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:14 |
| Symbol | NSRX |
| Name | NASUS PHARMA LTD. |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE MKT |
| Listed Shares | 11.71 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27.32 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Yigal Alon 65, Tel Aviv-Yafo, Israel, 6744317
Phone: 972 3 573 6632
Website: https://www.nasuspharma.com
Description: Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
